Mitchell S. Levine - 15 Mar 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Chief Financial Officer
Issuer ticker: OCX
Reported as of: 15 Mar 2022
Net transaction value: +$29,150
SEC form: 4
Accepted by SEC: 15 Mar 2022, 16:19:52 UTC
Source filing: View source filing
Reporting owner signature: /s/ Mitch Levine

Key filing fact

Mitchell S. Levine filed Form 4 for Oncocyte Corp (OCX) on 15 Mar 2022.

Key facts

This page summarizes Mitchell S. Levine's Form 4 filing for Oncocyte Corp (OCX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Mar 2022, 16:19.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$29,150.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCX transaction

Common Stock, no par value

Purchase

Transaction value: $29,150
Shares: +25,000
Change %: +40%
Price: $1.17
Shares after: 87,080
Date: 15 Mar 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price of $1.166 per share represents a weighted average of prices ranging from $1.155 to $1.180 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.